Van ECK Associates Corp Has $129,000 Stake in STAAR Surgical (NASDAQ:STAA)

Van ECK Associates Corp grew its position in STAAR Surgical (NASDAQ:STAA) by 12.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,478 shares of the medical instruments supplier’s stock after purchasing an additional 393 shares during the quarter. Van ECK Associates Corp’s holdings in STAAR Surgical were worth $129,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in STAA. Arcadia Investment Management Corp MI acquired a new stake in STAAR Surgical during the third quarter worth approximately $37,000. Covestor Ltd grew its position in STAAR Surgical by 38.9% during the first quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier’s stock worth $103,000 after buying an additional 754 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in STAAR Surgical during the second quarter worth approximately $129,000. Larson Financial Group LLC acquired a new stake in STAAR Surgical during the second quarter worth approximately $130,000. Finally, nVerses Capital LLC grew its position in STAAR Surgical by 78.3% during the third quarter. nVerses Capital LLC now owns 4,100 shares of the medical instruments supplier’s stock worth $152,000 after buying an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Canaccord Genuity Group reduced their price target on STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a research report on Friday, November 1st. Stifel Nicolaus reduced their target price on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, August 26th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, STAAR Surgical currently has an average rating of “Hold” and a consensus price target of $43.33.

STAAR Surgical Stock Performance

Shares of STAA opened at $28.44 on Thursday. STAAR Surgical has a 52 week low of $26.66 and a 52 week high of $52.68. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of 64.64 and a beta of 0.61. The stock has a fifty day moving average of $31.46 and a 200-day moving average of $37.55.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.